2019年11月20日 · Equfina, developed by Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, “Meiji”) in Japan, is a once-daily oral treatment for Parkinson’s disease, and is selective and …

Equfina® 50mg TABLETS (safinamide mesilate, “Equfina”) for the indication of improvement of wearing-off phenomenon in patients with Parkinson’s disease under treatment with a drug …

Equfina is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) for improvement of wearing-off phenomenon as add-on therapy to a stable dose of levodopa (L …

HOW EQUFINA WORKS Equfina acts to increase the level of a substance called dopamine in the brain, which is involved in the control of movement and is present in reduced amounts in the …

Equfina is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of levodopa (L-dopa) alone or in combination with other PD …

Safinamide is a novel, selective, and reversible inhibitor of monoamine oxidase B expected to increase dopamine levels in the brain and improve the symptoms of Parkinson's disease. In …

2019年9月20日 · evaluate the efficacy and safety of two doses of safinamide (50 and 100 mg, once a day for 24 weeks) administered orally as add-on therapy in Japanese patients with …

2019年11月21日 · Equfina, developed by Meiji Seika Pharma Co., Ltd. in Japan, is a once-daily oral treatment for Parkinson’s disease, and is selective and reversible monoamine oxidase B …

Safinamide is a highly selective and reversible MAO-B inhibitor causing an increase in extracellular levels of dopamine in the striatum. Safinamide is indicated for the treatment of …

The usual adult dosage for oral use is 50 mg of safinamide once daily. The dosage for oral use may be administered at 100 mg once daily according to the patient’s condition. Co …